Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the FDA for approval on Thursday. Eli Lilly’s LLY drug is called orforglipron.
Dec 18 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Thursday it had filed a marketing application with the U.S. Food and Drug Administration for CagriSema, its once-weekly ...
Novo Nordisk (NVO) announced on Thursday it filed a U.S. marketing application for its next-gen weight loss therapy, CagriSema, which combines its blockbuster obesity drug semaglutide with an amylin ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Toyota's $13.9 billion ...
A new weight-loss drug that Eli Lilly is testing is helping patients in a late-stage trial lose an average of 28.7% of their body weight and offered "substantial" relief from osteoarthritis pain. In ...
Eli Lilly LLY0.50%increase; green up pointing triangle said its next generation weight-loss drug retatrutide helped people lose up to 28.7% of their body weight after more than a year of treatment, ...
Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Eli Lilly’s ...
Eli Lilly and Co. (NYSE: LLY) on Tuesday today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. The synthetic medicine active pharmaceutical ...
Globally, more than 1 billion people currently live with obesity. The World Health Organization on Monday released new guidance on GLP-1 medications for adults with obesity, recommending their ...
The name "Ozempic 2.0" has been floating around on various outlets and on social media, as a trending nickname for the next generation of weight loss drugs that are in the works for 2026. Both Eli ...
“Ozempic is about to be old news,” my colleague Yasmin Tayag wrote in 2023, just before an even more powerful obesity drug, tirzepatide, then best known as Mounjaro, was approved. Well, two years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback